0001179110-20-006718.txt : 20200529 0001179110-20-006718.hdr.sgml : 20200529 20200529164032 ACCESSION NUMBER: 0001179110-20-006718 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200528 FILED AS OF DATE: 20200529 DATE AS OF CHANGE: 20200529 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: JANNEY DANIEL CENTRAL INDEX KEY: 0001198325 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35986 FILM NUMBER: 20928619 MAIL ADDRESS: STREET 1: ONE EMBARCADERO CENTER SUITE 3700 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Esperion Therapeutics, Inc. CENTRAL INDEX KEY: 0001434868 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3891 RANCHERO DRIVE, SUITE 150 CITY: ANN ARBOR STATE: MI ZIP: 48108 BUSINESS PHONE: 734-887-3903 MAIL ADDRESS: STREET 1: 3891 RANCHERO DRIVE, SUITE 150 CITY: ANN ARBOR STATE: MI ZIP: 48108 FORMER COMPANY: FORMER CONFORMED NAME: HDL THERAPEUTICS INC DATE OF NAME CHANGE: 20080513 4 1 edgar.xml FORM 4 - X0306 4 2020-05-28 0 0001434868 Esperion Therapeutics, Inc. ESPR 0001198325 JANNEY DANIEL C/O ESPERION THERAPEUTICS INC. 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR MI 48108 1 0 0 0 Common Stock 2020-05-28 4 A 0 6106 0.00 A 11073 D Common Stock 2018-02-28 4 J 0 24565 0.00 A 24565 I By Alta Bioequities, L.P. The shares vest in full on the earlier of (i) May 28, 2021 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2020. On February 28, 2018, Alta Partners VIII, L.P. ("APVIII") distributed 624,564 shares of Common Stock on a pro rata basis, for no additional consideration, to its partners, which distribution was exempt from Section 16 of the Exchange Act pursuant to Rule 16a-9 and Rule 16a-13. Alta Bioequities, L.P. ("Alta Bioequities") received 24,565 of these shares. Alta Bioequities Management, LLC is the general partner of Alta Bioequities L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC and may be deemed to have voting and investment power over the shares owned by Alta Bioequities, L.P. The 24,565 shares of Common Stock reported in this column as indirectly beneficially owned by the Reporting Person through Alta Bioequities were previously reported by the Reporting Person as indirectly beneficially owned through APVIII. These shares became indirectly beneficially owned by the Reporting Person through Alta Bioequities as a result of a pro rata distribution of shares described in footnote (2). /s/ Richard B. Bartram, by power of attorney 2020-05-29